TITLE

KEYDP/TEXAS BIOTECHNOLOGY SIGN RESEARCH PACT

PUB. DATE
February 2002
SOURCE
Worldwide Biotech;Feb2002, Vol. 14 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Provides information on the research agreement on protein structures between Key Drug Prototyping BV and Texas Biotechnology Corp.
ACCESSION #
6395308

 

Related Articles

  • Positive portent. Horton, Kathleen // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p96 

    Reports on Texas Biotechnology's announcement of positive results for its Phase III clinical trials involving the anticoagulant therapy Novastan for patients with heparin-induced thrombocystopenia and heparin-induced thrombocystopenia and thrombosis syndrome.

  • S.D. in the running for biotech complex. Fikes, Bradley J. // San Diego Business Journal;8/8/94, Vol. 15 Issue 32, p14 

    Reports on developments in biotechnology in San Diego, California as of August 8, 1994. Consideration of San Diego as one of two sites for a biotechnology complex to be built by BioPlex Group Inc. for Univax Biologics Inc.; Purchase of ImmunoPharmaceutics Inc. by Texas Biotechnology Corp.;...

  • IN THE PIPELINE.  // Drug Utilization Review;Sep2001, Vol. 17 Issue 9, p71 

    Presents an update related to drugs in the United States as of September 2001. Clinical trial on an anticancer compound from NeoOncoRx company; Drug approval given by the Food and Drug Administration to Texas Biotechnology Corp.; Supplemental biologic license application filed by Immunex Corp.

  • Deep in the Heart of Texas Bio--a Takeover? Leibs, Anthony // Mergers & Acquisitions Report;05/24/99, Vol. 12 Issue 21, p1 

    Discusses the need of Houston, Texas-based Texas Biotechnology Corp. (TBC) to make an alliance with commercially experienced corporate partner. Business and financial information on TBC; Comments from some industry analysts; Significance of the approval of Novastan, an anti-coagulant drugs...

  • Major Drug Companies Announce Research Deals.  // Chemical Market Reporter;06/12/2000, Vol. 257 Issue 24, p29 

    Reports that several drug companies have announced plans to focus their efforts on drug discovery research. Details on genomics and genetic research initiative of Roche company; Collaborative research deal of Sangamo BioSciences Inc. and R.W. Johnson Pharmaceutical Research Institute; Joint...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics